Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, a biotech company based in Tarrytown, NY, announced that the U.S. FDA has granted its Azedra™ (Ultratrace® iobenguane I 131) Breakthrough Therapy Designation for the treatment of patients with...

FDA Granted Breakthrough Status to Intercept’s Drug Obeticholic Acid (OCA) for Nonalcoholic Steatohepatitis (NASH)...

On January 29, Intercept Pharmaceuticals, Inc. (Intercept), headquartered in New York City, NY announced that its investigational new drug obeticholic acid (OCA) has received breakthrough therapy designation (BTD) from the U.S....

FDA Approved Natpara, the First Biologic to Treat a Rare Disease, Hypoparathyroidism

NPS Pharmaceutical, Inc., headquartered in Bedminster, New Jersey, USA, won FDA approval on January 23, 2015 for Natpara, the first bioengineered replacement therapy cleared for U.S. marketing to treat hypoparathyroidism.  FDA...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...